120 related articles for article (PubMed ID: 2480798)
1. Lack of HPA-23 antiviral activity in HIV-infected patients without AIDS.
Burgard M; Sansonetti P; Vittecoq D; Descamps P; Guetard D; Herson S; Rozenbaum W; Rouzioux C
AIDS; 1989 Oct; 3(10):665-8. PubMed ID: 2480798
[TBL] [Abstract][Full Text] [Related]
2. Reverse transcriptase activity (RTA) in lymphocyte cultures of HIV-infected patients receiving short treatments of HPA 23. A biological evaluation.
Vittecoq D; Woerle R; Barre-Sinoussi F; Chermann JC
Biomed Pharmacother; 1988; 42(1):35-9. PubMed ID: 2457397
[TBL] [Abstract][Full Text] [Related]
3. Transient elevation of serum HIV antigen levels associated with intercurrent infection.
Claydon EJ; Bennett J; Gor D; Forster SM
AIDS; 1991 Jan; 5(1):113-4. PubMed ID: 1905552
[No Abstract] [Full Text] [Related]
4. Kinetics of p24 antigenemia, IgM, IgG antibodies to p24 and p41 and Ig virus isolation in rabbits experimentally infected with HIV-1.
Filice G; Cereda PM; Orsolini P; Soldini L; Romero E; Rondanelli EG
Microbiologica; 1990 Jul; 13(3):215-24. PubMed ID: 2125683
[TBL] [Abstract][Full Text] [Related]
5. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S
Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362
[TBL] [Abstract][Full Text] [Related]
6. Racial heterogeneity of HIV antigenemia in people with HIV infection.
Chaisson RE; Fuchs E; Stanton DL; Quinn TC; Hendricksen C; Bartlett JG; Farzadegan H
AIDS; 1991 Feb; 5(2):177-80. PubMed ID: 1903261
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of HIV-1 p24 antigenemia in African and North American populations and correlation with clinical status.
Brown C; Kline R; Atibu L; Francis H; Ryder R; Quinn TC
AIDS; 1991 Jan; 5(1):89-92. PubMed ID: 1905553
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus (HIV)-infected tumor xenografts as an in vivo model for antiviral therapy: role of alpha/beta interferon in restriction of tumor growth in nude mice injected with HIV-infected U937 tumor cells.
Puddu P; Locardi C; Sestili P; Varano F; Petrini C; Modesti A; Masuelli L; Gresser I; Belardelli F
J Virol; 1991 May; 65(5):2245-53. PubMed ID: 1901915
[TBL] [Abstract][Full Text] [Related]
9. Donor HIV-1 p24 antigenaemia and course of infection in recipients Transfusion Safety Study Group.
Busch MP; Donegan E; Stuart M; Mosley JW
Lancet; 1990 Jun; 335(8701):1342. PubMed ID: 1971398
[No Abstract] [Full Text] [Related]
10. Zidovudine treatment of an infant with congenital human immunodeficiency virus infection.
Millard DD; Chadwick EG; Yogev R; Modlin JF
Pediatr Infect Dis J; 1990 Dec; 9(12):929-31. PubMed ID: 2126136
[No Abstract] [Full Text] [Related]
11. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).
Jacobsen MA; van der Horst C; Causey DM; Dehlinger M; Hafner R; Mills J
J Infect Dis; 1991 Jun; 163(6):1219-22. PubMed ID: 1828075
[TBL] [Abstract][Full Text] [Related]
12. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals.
Nishanian P; Huskins KR; Stehn S; Detels R; Fahey JL
J Infect Dis; 1990 Jul; 162(1):21-8. PubMed ID: 2113075
[TBL] [Abstract][Full Text] [Related]
13. CD4 lymphocyte counts and serum p24 antigen of no diagnostic value in monitoring HIV-infected patients with pulmonary symptoms.
Orholm M; Nielsen TL; Nielsen JO; Lundgren JD
AIDS; 1990 Feb; 4(2):163-6. PubMed ID: 1970256
[TBL] [Abstract][Full Text] [Related]
14. Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine.
Williams IG; Gabriel G; Kelly G; Loveday C; Tedder RS; Weller IV
AIDS; 1990 Sep; 4(9):909-12. PubMed ID: 2123627
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection.
Davey RT; Davey VJ; Metcalf JA; Zurlo JJ; Kovacs JA; Falloon J; Polis MA; Zunich KM; Masur H; Lane HC
J Infect Dis; 1991 Jul; 164(1):43-52. PubMed ID: 1676045
[TBL] [Abstract][Full Text] [Related]
16. Immune activation markers and AIDS prognosis.
Osmond DH; Shiboski S; Bacchetti P; Winger EE; Moss AR
AIDS; 1991 May; 5(5):505-11. PubMed ID: 1677808
[TBL] [Abstract][Full Text] [Related]
17. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection.
Kimberlin RH; Walker CA
Arch Virol; 1983; 78(1-2):9-18. PubMed ID: 6686005
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of IL-2, IL-1 alpha, TNF-alpha, and soluble receptor of IL-2 in HIV-1-infected patients.
Scott-Algara D; Vuillier F; Marasescu M; de Saint Martin J; Dighiero G
AIDS Res Hum Retroviruses; 1991 Apr; 7(4):381-6. PubMed ID: 1676897
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS.
Kimura S; Matsuda J; Ikematsu S; Miyazono K; Ito A; Nakahata T; Minamitani M; Shimada K; Shiokawa Y; Takaku F
AIDS; 1990 Dec; 4(12):1251-5. PubMed ID: 1708265
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients.
Mulder JW; Krijnen P; Goudsmit J; Schattenkerk JK; Reiss P; Lange JM
Genitourin Med; 1990 Jun; 66(3):138-41. PubMed ID: 2115018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
